Once FDA approval is rendered (the "delay" is most likely a technicality due to events beyond the control of BMSN) and the MIN IND application is submitted, the possibilities are endless because so much of this science has been proved in various ways over the course of forty years. Efficacy is not a question. And if you read outside the box with regard to the preclinical data, you will find that safety is not a question. That being said, once these two (FDA approval and the MIN IND application) are confirmed, then a true valuation of the company can commence.


HemaXellerate is but one scion of the primary, HemXellerate. They aim to treat various diseases with this stem cell approach. Min/Benitec science...targeting cancer genes, silencing them AND teaching the body to search out escaped cancer cells and destroying them, while at the same time healing itself...the market potential is astronomical. The company valuation is unreal after this.

Getting there is what has been so grueling. Then so is the task of fighting diseases that have plagued mankind predating history.

BMSN